I,like some,have misread the tape on this one:not unusual in Bio-Tech speculation.Games are being played with the SP,causing mild discomfort.Have to be long here[in hindsight].The health saga in America has implications for the Company.Despite Government claims,Health-Care costs will rise:medical device makers expect this to happen.The cost of additional insurance for 32 million will damage the Health system:companies will not pass on their savings to the consumer.There is 30 trillion in unfunded liabilities ticking away.The investor[i wish I could trade it!],must decide if the glass is half full or empty:Karmelsonix products will become too expensive for health over-counter sales or the 32 million additional insurance will increase opportunities for marketing. I still am confident that it is the increasing stresses on the health system that may create greater need for outsourcing emergency services such as asthma management.And so we wait....
KSX Price at posting:
3.0¢ Sentiment: LT Buy Disclosure: Held
